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Breast cancer bone metastasis is currently incurable, ~75% of patients with late-stage breast cancer develop disease recurrence in
bone and available treatments are only palliative. We have previously shown that production of the pro-inflammatory cytokine
interleukin-1B (IL-1B) by breast cancer cells drives bone metastasis in patients and in preclinical in vivo models. In the current study,
we have investigated how IL-1B from tumour cells and the microenvironment interact to affect primary tumour growth and bone
metastasis through regulation of the immune system, and whether targeting IL-1 driven changes to the immune response
improves standard of care therapy for breast cancer bone metastasis. Using syngeneic IL-1B/IL1R1 knock out mouse models in
combination with genetic manipulation of tumour cells to overexpress IL-1B/IL1R1, we found that IL-1B signalling elicited an
opposite response in primary tumours compared with bone metastases. In primary tumours, IL-1B inhibited growth, by impairing
the infiltration of innate immune cell subsets with potential anti-cancer functions but promoted enhanced tumour cell migration. In
bone, IL-1B stimulated the development of osteolytic metastases. In syngeneic models of breast cancer, combining standard of care
treatments (Doxorubicin and Zoledronic acid) with the IL-1 receptor antagonist Anakinra inhibited both primary tumour growth
and metastasis. Anakinra had opposite effects on the immune response compared to standard of care treatment, and its anti-
inflammatory signature was maintained in the combination therapy. These data suggest that targeting IL-1B signalling may provide
a useful therapeutic approach to inhibit bone metastasis and improve efficacy of current treatments for breast cancer patients.
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INTRODUCTION
Breast cancer (BC) is the second most common cancer worldwide
(2.26 million cases in 2020), accounting for 685,000 deaths (https://
www.who.int/news-room/fact-sheets/detail/cancer, 2020). The major-
ity of cancer-related deaths result from tumours spreading to distal
sites after which point the disease is currently incurable.
Bone is the most common metastatic site in BC—75% of patients
with late-stage BC experience recurrence in bone—followed by
lung, liver and brain1–3. Once tumour cells disseminate in bone they
enter state of dormancy before cell-autonomous mechanisms and
cellular interactions with the bone microenvironment stimulates
proliferation and development of overt metastases4–7. The role of
the immune system in controlling metastatic tumour cell dormancy
in bone remains to be explored8. As current treatments for
metastatic breast cancer are predominantly palliative, there is an
urgent clinical need to identify new biomarkers of metastatic BC
and to develop more effective therapies9.
We recently identified the pro-inflammatory cytokine
Interleukin-1B (IL-1B) as a marker of breast cancer bone metastasis
and showed that pharmacological targeting of IL-1B or its receptor
(IL1R1) impairs bone metastasis10–13. We and others have
previously shown that tumour-derived IL-1B drives EMT11,14. We
suggested that inhibition of IL-1B using Canakinumab supports an
epithelial rather than a mesenchymal phenotype thus, favoring
tumour proliferation while inhibiting EMT and therefore
metastasis11.
The tumour cell is not the only source of IL-1B; cells in the
microenvironment, including immune cells, endothelial cells,
osteoblasts and bone marrow cells produce IL-1B. The arrival of
tumour cells in bone triggers further production of IL-1B from
tumour cells as well as IL-1B release from cells within the bone
marrow11. This microenvironmental increase in IL-1B promotes
metastatic colonisation of bone via Wnt signalling15 as well as
stimulating expansion of the bone metastatic (osteoblastic and
vascular) niches11. Moreover, IL-1B produced by macrophages
infiltrating the primary tumour, initiates a systemic neutrophilic
inflammatory response that ultimately results in CD8+ T cell
inhibition, immunosuppression and metastasis to the lungs16,17.
Since IL-1B causes immunosuppression18, inhibition of this
cytokine in combination with immunotherapies has been found to
promote anti-tumour immunity and impair primary tumour
growth19. Therefore, administration of anti-IL-1 therapies in
combination with immune-stimulatory drugs may provide effec-
tive therapeutic options for patients with breast cancer. The
chemotherapeutic compound Doxorubicin is an anthracycline
commonly used to treat breast cancer and bone metastasis. This
drug stops tumour proliferation by targeting the topoisomerase 2
enzyme and induces inflammatory cell death (ICD)20,21 leading to
infiltration of immune cells.
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In addition to chemotherapy, breast cancer bone metastases
are commonly treated with zoledronic acid. We have previously
shown that combining doxorubicin with zoledronic acid synergis-
tically increases the anti-tumour effects of doxorubicin when
given in sequence22–24. When translated into the clinic, adding
zoledronic acid to standard of care in an adjuvant setting reduced
bone metastases in all patient groups. However, this combination
only had life prolonging benefits in women with established
menopause by reducing tumour recurrence in any tissue. In pre-
menopausal women, the same treatment resulted in increased
development of soft tissue metastasis25. Interestingly, patients
who did worse with this combination treatment had higher levels
of IL-1B in their primary tumours than those that responded
well11. It is therefore possible that adding anti-IL-1 treatment to
doxorubicin and zoledronic acid may increase the anti-metastatic
effects of these drugs in a pre-menopausal setting.
In the current study, we investigate how IL-1B from different
environments influences immune cell abundance, driving primary
tumour growth and bone metastasis and whether this has an
effect on the response to standard of care therapies. We
hypothesise that combining doxorubicin and zoledronic acid with
anti-IL-1 treatments may increase the therapeutic effects of
standard of care by increasing tumour cell killing at both primary
and metastatic sites. We found that both tumour and
microenvironment-derived IL-1B drive the infiltration of immune
cells which may harbour anti-tumour functions in breast primary
tumours, however, in bone, IL-1B supports metastasis formation.
By maintaining its anti-inflammatory effect, anti-IL-1 therapy leads
to increased efficacy of standard of care treatment for bone
metastasis. Our new data strongly suggest that adding anti-IL-1
treatment to standard of care therapy is a potential effective
treatment for patients with breast cancer.
RESULTS
Microenvironment-derived IL-1B controls primary breast
tumour development
We previously showed that pharmacological inhibition of IL-1B
signalling using the IL-1Ra, Anakinra, did not affect the growth of
the primary tumour, whereas treatment with an anti-IL-1B
antibody, Canakinumab, increased proliferation. Since pharmaco-
logical treatments can equally affect the tumour as well as the
stroma and previous experiments had used immune-
compromised mice, we next addressed the contribution of
microenvironment-derived IL-1B on primary tumour growth and
immune response to breast cancer in orthotopic models. To
model a microenvironment in which IL1R1 or IL-1B is absent, mice
with a ubiquitous IL1R1 KO (K14Cre; Il1r1fl/fl)26,27 or IL-1B KO
(PGKCre; Il1bfl/fl) (Supplementary Fig. 1) were used along with
correspondent IL1R1fl/fl or IL-1Bfl/fl mice as control. In these
models, we found that inhibition of IL1R1 did not affect primary
tumour growth (Fig. 1a, b), whereas inhibition of IL-1B resulted in


























Fig. 1 Depletion of IL-1B but not IL1R1 from the microenvironment promotes primary tumour growth. a Quantification (photons/sec (p/s))
of primary tumour growth in IL1R1fl/fl (n= 8 primary tumours from n= 4 mice) and IL1R1−/− (n= 8 primary tumours from n= 4 mice) mice up
to 12 days of post-orthotopic injection of E0771-luc2-V5-GFP cells and b correspondent micrographs. c Quantification (p/s) of primary tumour
growth in IL-1Bfl/fl (n= 7) and IL-1B−/− (n= 6) mice up to 26 days of post-orthotopic injection of E0771-luc2- GFP cells and d correspondent
micrographs. IL-1Bfl/fl: n= 13 primary tumours from n= 7 mice (day 7 and 14); n= 12 primary tumours from n= 6 mice (day 20 and 26).
IL-1B−/−: n= 12 primary tumours from n= 6 mice (day 7); n= 10 primary tumours from n= 6 mice (day 14, 20, and 26). 2.3-fold increase in
primary tumour growth in IL-1B−/− mice (7.6 × 108 p/s) compared to IL-1Bfl/fl mice (3.2 × 108 p/s) (P= 0.01). Data are mean +/− SEM, Two-way
ANOVA with Sidak’s post-hoc test.
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recapitulating the effect that we had previously seen following
pharmacological inhibition of IL-1B signalling11.
Microenvironment-derived IL-1B impairs primary tumour
growth whilst recruiting different subsets of innate immune
cells
As genetic removal of IL-1B or IL1R1 in syngeneic mouse models
or pharmacological suppression of this cytokine/receptor in
immune-compromised (T and B cell deficient) mouse strains led
to the same effects, we hypothesised that IL-1B controls the
growth of the primary tumour independently of the adaptive
immune response. We therefore investigated the contribution of
IL-1 driven changes in primary tumour growth focusing on
infiltration of innate immune cell subsets using immunohisto-
chemistry (IHC). Our data showed that lack of IL-1B resulted in
increased primary tumour growth and decreased infiltration of
MPO+ neutrophils and F4/80+ macrophages (Fig. 2a–c). Next, we
evaluated the infiltration of specific subsets of iNOS+ anti-tumour
immune cells (M1-like macrophages)28 and CD163+ pro-tumour
M2-like macrophages29. Since M2-like macrophages have pro-
angiogenic functions30, we stained for CD34+ blood vessels within
the primary tumour. We found that IL-1B regulates iNOS+ immune
cell infiltration, without affecting either the accumulation of
CD163+ immune cells or the growth of tumour-associated CD34+
blood vessels (Fig. 2d–g). Furthermore, we observed that iNOS+
immune cells localise specifically in viable regions, whereas
CD163+ M2-like macrophages and MPO+ neutrophils were found
in areas of necrosis (Fig. 2h–j). IL-1B ablation in the microenviron-
ment removed this spatial bias, resulting in an equal number of
iNOS+ and CD163+ macrophages in both areas of tumour viability
and necrosis (Fig. 2k, l). MPO+ neutrophils localised in areas of
necrosis and their distribution was not altered upon IL-1B ablation
in the microenvironment (Fig. 2m). Taken together, these findings
suggest that microenvironment-derived IL-1B may control breast
primary tumour growth by driving an innate immune response,
with potential anti-tumour functions.
Tumour-derived IL-1B limits primary tumour development
and re-establishes the infiltration of immune cells with
potential anti-tumour functions
After addressing the role of stromal-derived IL-1B signalling by
using parental E0771 in mice lacking IL-1B or IL1R1, next we
investigated whether tumour-derived IL-1B rescues the lack of
microenvironment-derived IL-1B. For this, we engineered E0771 to
overexpress IL-1B (Supplementary Fig. 2A, C) and performed an
orthotopic engraftment in IL-1Bfl/fl and IL-1B−/− mice. We found
that in IL-1B−/− mice there was a significant reduction in tumour
growth compared to IL-1Bfl/fl mice (Fig. 3a, b) (for comparison the
injection of the parental cell line can be observed in Fig. 1c, d). As
tumour-derived IL-1B compensated for the absence of
microenvironment-derived IL-1B, we next hypothesised that IL-
1B production by tumour cells restores the infiltration of innate
immune cells that may harbour anti-tumour functions, resulting in
a reduction in primary tumour growth. Therefore, we quantified
macrophages and neutrophils in primary tumours overexpressing
IL-1B from IL-1Bfl/fl and IL-1B−/− mice using IHC. We found an
increase in F4/80+ macrophages in tumours growing in IL-1B−/−
mice in the periphery of the tumour compared to the core of the
tumour (Fig. 3c). However, no differences were observed in
primary tumours growing in IL-1Bfl/fl mice, suggesting that
tumour-derived IL-1B induces F4/80+ macrophage recruitment
(Fig. 3c). We also assessed the infiltration of CD163+ macrophages
in primary tumours overexpressing IL-1B in IL-1Bfl/fl and IL-1B−/−
mice. We found an increase in CD163+ macrophages in the
tumour periphery compared to the tumour core, suggesting
increased macrophage recruitment (Fig. 3d). However, no
significant difference was observed in CD163+ macrophages
between tumour core and tumour periphery in IL-1B deficient
mice (Fig. 3d). In line with impaired M2-like macrophage
infiltration, we observed a decrease in CD34+ blood vessels in
tumours growing in an IL-1B ablated microenvironment (Fig. 3e).
In agreement with our hypothesis that tumour-derived IL-1B
drives an anti-tumour response, we quantified the infiltration of
neutrophils in primary tumours and found a tendency for an
increase in MPO+ neutrophils (Fig. 3f). Next, we orthotopically
engrafted IL-1B overexpressing E0771 in IL1R1fl/fl and IL1R1−/−
mice and hypothesised that IL-1B does not trigger an immune
response in an IL1R1 deficient microenvironment. We found that
the growth of IL-1B overexpressing primary tumours was
increased in IL1R1−/− mice compared to IL1R1fl/fl mice (Fig.
3g–h), suggesting that tumour-derived IL-1B can no longer exert
its anti-tumour functions in IL1R1-deficient microenvironments. In
conclusion, these data suggest that tumour derived IL-1B activates
the innate immune response with potential anti-tumour functions.
Both tumour-derived and microenvironment-derived IL-1B pro-
mote the infiltration of immune cells that may exert anti-tumour
functions, impairing the growth of breast cancer at the primary
site.
Tumour-derived IL-1B signalling supports breast cancer
metastasis by enhancing tumour cell motility and inhibiting
cell proliferation
We and others have previously shown that tumour-derived IL-1B
drives EMT11,14. We suggested that inhibition of IL-1B using
Canakinumab supports an epithelial rather than a mesenchymal
phenotype thus, favoring tumour proliferation while inhibiting
EMT and therefore metastasis11. In order to address the role of
tumour-derived IL-1B signalling in an immune-competent syn-
geneic model, we orthotopically injected IL1R1-overexpressing
E0771 (Supplementary Fig. 2B, D) mouse mammary tumour cells
in IL1R1fl/fl and IL1R1−/− mice. In this model, IL-1B signalling is
only active in tumour cells. We found that tumour-derived
IL1R1 signalling decreased primary tumour growth in microenvir-
onment of IL1R1 deficient mice compared to control IL1R1fl/fl mice
(Fig. 4a, b) (for comparison the injection of the parental cell line
can be observed in Fig. 1a, b). Moreover, using an MTT
proliferation assay we found that tumour cells overexpressing
IL1R1 displayed reduced proliferation compared to control cells
when stimulated with exogenous IL-1B (Fig. 4c). In contrast,
E0771 cells overexpressing IL-1B or IL1R1 were found to be more
invasive than control cell line. Moreover, E0771 cells overexpres-
sing IL1R1 were significantly more invasive than cells over-
expressing IL-1B (Fig. 4d, e). Taken together, these data suggest
that tumour-derived IL-1B signalling, via IL1R1 activation, inhibits
primary tumour growth, while enabling tumour invasion.
Microenvironment-derived IL-1B enhances breast cancer
metastasis in bone
To investigate the effects that microenvironment-derived IL-1B
has on breast cancer bone metastasis, E0771 mammary cancer
cells were injected into the blood circulation of IL-1Bfl/fl and IL-
1B−/− mice via intra-cardiac injection. Bone metastasis, as
quantified using bioluminescence, was significantly reduced by
95% in IL-1B−/− mice (1.7 × 104 p/s) compared to the IL-1Bfl/fl
group (3.6 × 105 p/s, P= 0.0196) (Fig. 5a, b, and d). In the IL-1B−/−
group, 2/9 (22.2%) mice developed bone metastasis, compared to
6/9 (66.7%) mice within the IL-1B fl/fl group. Osteolytic metastases
were observed in IL-1Bfl/fl mice using µCT imaging (Fig. 5c),
whereas osteolytic lesions were absent in IL-1B−/− mice (Fig. 5e).
No significant difference was found in osteoclast and osteoblast
activity, when IL-1Bfl/fl mice injected with tumour cells were
compared with IL-1B−/− (Supplementary Fig. 3). Overt metastases
replaced part of the tibial bone marrow in IL-1Bfl/fl (Fig. 5f), which
was still present in IL-1B−/− mice (Fig. 5g), based on H&E staining.
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Next, we monitored innate immune cells at this site using multi-
colour flow cytometry. We found that a decrease in bone
metastases upon depletion of microenvironment-derived IL-1B
was accompanied by a significant increase in the proportion of
CD45+ immune cells (Fig. 5h). The increase in CD45+ immune cells
was accompanied by an increase in CD45+ CD11b+ myeloid cells
(Fig. 5i), whereas there was no difference in CD45+ CD11b−
CD11c− lymphoid cells (Fig. 5j). The increase in CD45+ CD11b+
myeloid cells was reflected by an increase in CD45+
CD11b+ Ly6G+ neutrophils (Fig. 5k), whereas no difference in
CD45+ CD11b+ F4/80+ macrophages was observed (Fig. 5l).
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1B promotes breast cancer bone metastasis in vivo. Because IL-1B
displays opposite functions in primary breast tumour and bone
metastasis, its role in metastatic breast cancer may be tissue-
specific.
Combining Anakinra with Doxorubicin and Zoledronic acid
inhibits breast cancer growth at the primary site and distant
recurrence, in pre-clinical models of breast cancer metastasis
Our data show that IL-1B drives the recruitment of innate immune
cells, and whilst IL-1B is protective in the primary tumour, it drives
metastasis in bone. We, therefore, investigated whether targeting
IL-1B in combination with standard of care agents that have
immune-modulatory effects impairs primary tumour growth as
well as metastasis. For this purpose, we used IL-1 receptor
antagonist, Anakinra, an anti-inflammatory drug, in combination
with Doxorubicin (Dox) and Zoledronic acid (Zol), both pro-
inflammatory, in a syngeneic pre-clinical in vivo model of
spontaneous breast cancer metastasis. Bone homing mouse
mammary tumour cells (E0771) were orthotopically engrafted in
6–8 week-old C57BL/6 female mice. Nine days after tumour cell
injection, mice were randomised to the following groups: placebo
(P) (n= 8) (daily by subcutaneous injection), Anakinra (n= 8) (daily
by subcutaneous injection), Dox (weekly by intra-venous injection)
followed 24 h later by Zol (n= 8) (weekly by subcutaneous
injection), and the combination treatment Anakinra, Dox, and Zol
(n= 8). We found that Anakinra alone significantly increased the
growth of primary tumours, however, adding Dox and Zol to
Anakinra significantly decreased primary tumour growth, com-
pared to Anakinra alone, (12 days of post-treatment) (Fig. 6a),
without affecting cell proliferation (Fig. 6b) but by inducing cell
apoptosis (Fig. 6c, d).
Using the same cohort of animals, we then investigated the
effect of the single and combined treatments on metastases in
bone and other organs (lungs and liver), in the spontaneous
metastasis model. Anakinra alone reduced the percentage of
animals showing metastasis in bone (50% compared to 85.71% in
the placebo treated group) and liver (37.5% vs. 42.86% in the
placebo). Similarly, Dox and Zol alone treatment resulted in a
reduction in bone (50% vs. 85.71% in the placebo) and liver
metastasis (25% vs. 42.86% in the placebo). However, both
Anakinra alone and Dox and Zol alone caused an increase in the
percentage of animals with lung metastasis (75% Anakinra, 87.5%
Dox and Zol, and 71.43% in placebo). Combining Anakinra with
Dox and Zol reduced metastasis in lungs (28.57% vs. 71.43% in the
placebo), liver (14.29% vs. 42.86% in the placebo) and significantly
impaired metastasis in bone (14.29% vs. 85.71% in the placebo)
(Fig. 6e, f).
We next investigated the effect of combining Anakinra with Dox
and Zol on outgrowth of disseminated breast cancer cells in
metastatic organs. For this, immunocompetent 6–8 week-old
C57BL/6J or BALB/c female mice received an intra-cardiac
injection of luciferase expressing E0771 or 4T1 mouse mammary
tumour cells, respectively and the development of metastasis was
monitored using in vivo bioluminescence imaging. Mice were
randomised into the following treatment groups 2 days after
tumour cell injection: placebo, Anakinra, Dox and Zol and the
combination of Anakinra, Dox and Zol. In the E0771/C57BL/6J
model, in vivo bioluminescence imaging of bone, liver, and lungs
was performed in end-stage mice 16 days of post-treatment. Our
data showed that the percentage of animals showing bone
metastasis was reduced upon Anakinra (16.67% vs. 50% in the
placebo) or Dox and Zol treatment (0% vs. 50% in the placebo).
However, the percentage of animals showing metastatic out-
growth in other sites was increased with Anakinra treatment
(83.33% vs. 50% in the placebo), but remained unaltered in the
Dox and Zol group (50% following Dox and Zol). Importantly,
combining Anakinra with Dox and Zol resulted in a striking
reduction in both bone and distant metastasis (overt metastases
in bones from 0% of animals and in other organs from 16.67% of
animals) (Fig. 6g, h). In confirmation of our findings, we did not
observe a difference in bone metastasis when comparing the
treatments Anakinra, Anakinra+Zol, and Anakinra+Dox (Supple-
mentary Fig. 4). Therefore, we combined Anakinra with Dox+Zol
and concluded that only triple treatment is superior in reducing
tumour growth in both bone and soft tissue.
In the 4T1/BALBc model, 25% of animals in the placebo group
developed bone metastasis, compared to 12.5% in the Anakinra
group whereas no bone metastases were observed after Dox and
Zol treatment. Combining Anakinra to Dox and Zol resulted in a
reduction in bone metastasis compared to placebo, similarly to
the Anakinra treatment alone. The combination treatment also
reduced metastasis elsewhere (57.1% of the animals developed
metastasis compared to 87.5% in the placebo treated group) (Fig.
6i, j). The combination treatment did not display damaging effects
on bone formation in any of the pre-clinical models used in this
study (Fig. 6k–m). Hence, combining IL-1B signalling inhibition
with standard of care is a promising treatment for breast cancer
bone metastasis.
Combining Anakinra with Doxorubicin and Zoledronic affects
primary tumour immune cell composition
Since the chosen treatments, both alone and in combination,
altered the immune response, we used NanoString
amplification-free gene expression profiling technology to
identify the immune signature of breast primary tumours and
the subsequent development of distant metastasis in bone and
other organs. Using the NanoString nCounter™ panCancer
mouse Immune Profiling Panel, we found that, amongst an
expected enrichment in immune cell pathways, cytokine
production, cytokine–cytokine receptor interaction, cell chemo-
taxis, and specifically myeloid leucocyte migration were
enriched (Supplementary Fig. 5). Anakinra treatment caused
opposite effects on immune response compared to Dox and Zol.
The PCA plot and the hierarchical cluster analysis showed that
an anti-inflammatory signature was observed after Anakinra
treatment compared to Dox+Zol (Fig. 7a, b). Cell signature
Fig. 2 Microenvironment-derived IL-1B drives the infiltration of innate immune cells with putative anti-tumour function and promotes
immune cell subset positioning in primary breast tumours. a MPO+ neutrophils (*P= 0.01) and b F4/80+ macrophages (*P= 0.03) in the
primary tumour of IL-1Bfl/fl and IL-1B−/− mice. Each dot represents a tissue section from a primary tumour isolated from each mouse. c
Representative IHC micrographs of MPO and F4/80 staining. d iNOS+ (*P= 0.04), e CD163+ (ns) and f CD34+ (ns) cells in the primary tumour of
IL-1Bfl/fl and IL-1B−/− mice. d, e Each dot represents an inner or outer section from a primary tumour obtained from each mouse. f Each dot
represents a tissue section from a primary tumour isolated from each mouse. g Representative IHC micrographs of iNOS, CD163 and
CD34 staining. Data are mean +/− SEM Two-tailed unpaired t-test with Welch’s correction. Scale bar: 50 µm. h iNOS+ cells in viable and
necrotic areas of the primary tumour (tissue section from the tumour core) (P= 0.016) of IL-1Bfl/fl mice determined by IHC. i CD163+ cells in
viable and necrotic areas of the primary tumour (P= 0.016) of IL-1Bfl/fl mice determined by IHC. j MPO+ neutrophils in viable and necrotic
areas of IL-1Bfl/fl (P < 0.0001). k iNOS+ cells in viable and necrotic regions of primary tumours from IL-1B−/− mice. l CD163+ cells in viable and
necrotic areas of primary tumours from IL-1B−/− mice. m MPO+ neutrophils in viable and necrotic areas of IL-1B−/− (P < 0.0001) mice. Data are
shown as mean +/− SEM, Two-tailed unpaired t-test with Welch’s correction, ns non-significant. Scale bar: 50 µm in h, i, k, l. Scale bar: 20 µm in
j and m.
C. Tulotta et al.
5











































































































Fig. 3 Tumour-derived IL-1B restores the infiltration of innate immune cells that may display anti-tumour functions and inhibits primary
tumour growth in an IL-1B deficient microenvironment. a, b Images and quantification of primary tumour development in IL-1Bfl/fl (n= 8
primary tumours from n= 4 mice) and IL-1B−/− (n= 10 primary tumours from n= 5 mice) mice after intra-ductal administration of E0771 Luc2
V5 IL-1B-GFP cells. Data are mean +/− SEM, Two-way ANOVA with Sidak’s post-hoc test. c, d Quantification of F4/80+ macrophages (c) and
CD163+ macrophages (d) in tumour core and periphery in IL-1Bfl/fl and IL-1B−/− mice. Data are mean ± SEM, Two-way ANOVA with Sidak’s post
hoc test. e, f Quantification of CD34+ blood vessels and MPO+ neutrophils in IL-1Bfl/fl and IL-1B−/− mice. Data are shown as mean +/− SEM,
Two-tailed unpaired t-test. g, h Images and quantification of primary tumour development in IL1R1fl/fl (n= 18 primary tumours from n= 9
mice) and IL1R1−/− (n= 14 primary tumours from n= 7 mice) mice after intra-ductal administration of E0771 Luc2 V5 IL-1B-GFP. Normalised
data are shown as mean +/− SEM, Two-tailed unpaired t-test.
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analysis demonstrated reduced abundance of every immune cell
type, such as B cells, T cells (including CD8+ T cells, Th1 cells,
exhausted CD8+ T cells and immunoregulatory (Treg) cells,
dendritic cells (DCs), macrophages, mast cells, neutrophils and
NK cells, including, CD56dim (‘cytotoxic’) NK cells compared to
control group following Anakinra treatment (Fig. 7c, d). The anti-
inflammatory effect of Anakinra was maintained in the
combination treatment with Dox+Zol, resulting in a reduced
immune cell abundance. Interestingly, macrophages and mast
cells were further reduced upon triple treatment compared to
any other treatment group, in contrast, T regulatory cells were
increased. As the combination treatment significantly reduced
primary tumour growth and distant recurrence, while causing an
increase in Treg cells alongside a decrease in immune cells with
cytotoxic functions, including CD56dim (cytotoxic) NK cells and
CD8+ (cytotoxic) T cells, we suggest that an anti-tumour
immune response may have been induced. In support of the
cell signature analysis, IHC for CD8+ T cells and Granzyme B
demonstrated CD8+ T cell infiltration of primary tumours, but
that exhaustion had already taken place (i.e., an absence of
6



































































Fig. 4 IL-1B signalling enables breast cancer metastasis initiation. a, b Tumour proliferation after injection of E0771 luc2 V5 IL1R1-GFP cells
in IL1R1fl/fl (n= 8 primary tumours from n= 4 mice) and IL1R1−/− (n= 6 primary tumours from n= 3 mice) mice. Data are mean +/− SEM,
Two-way ANOVA with Sidak’s multiple comparisons test. c In vitro relative tumour growth of E0771 luc2 V5 GFP, IL-1B GFP or IL1R1 GFP cells
upon stimulation with 40 pg/ml mouse recombinant IL-1B. Data are mean (+/− SEM), Two-way ANOVA with Sidak’s multiple comparison test
(n= 6 technical repeats from two biological replicates). d Transwell cell migration of IL-1B overexpressing (P= 0.0009) and IL1R1
overexpressing (P < 0.0001) E0771 luc2 V5 cancer cells compared to control GFP-expressing cells (no treatment with exogenous IL-1B).
Comparison of cell migration in vitro between E0771 luc2 V5 IL-1B GFP and IL1R1 GFP tumour cells (P= 0.0018). Data are mean (+/− SEM) cell
number from 4 fields of view derived from three biological experiments (n= 12 technical repeats). Two-tailed unpaired t-test with Welch’s
correction. e Representative images of haematoxylin-stained control, IL-1B and IL-1R1 overexpressing cells migrated through the membrane.
Scale bar = 200 µm.
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Fig. 5 Microenvironment-derived IL-1B drives breast cancer bone metastases by controlling myeloid cell abundance. a Quantification
(photons/seconds) of bone metastases in IL-1Bfl/fl and IL-1B−/− mice after intra-cardiac administration of E0771 luc2 V5 GFP tumour cells. b
Representative bioluminescence micrographs of metastases in bone and distant locations in IL-1Bfl/fl mice. c µCT scans and f H&E staining of
tibia in tumour-bearing IL-1Bfl/fl mice. Scale bar = 100 µm. d Representative bioluminescence micrographs of metastases in bone and distant
locations in IL-1B−/− mice. e µCT scans and g H&E staining of tibia in tumour-bearing IL-1B−/− mice. H&E images: BM bone marrow, T tumour.
Data are mean ± SEM, Two-tailed unpaired t-test with Welch’s correction. Relative percentage of h immune cells (CD45+), i myeloid cells
(CD45+CD11b+), j lymphoid cells (CD45+ CD11b− CD11c−), k neutrophils (CD45+CD11b+Ly6G+) and l macrophages (CD45+ CD11b+ F4/80+)
in bone marrow samples from femurs of IL-1Bfl/fl (n= 9) and IL-1B−/− (n= 9) mice detected using multicolour flow cytometry. Data are mean ±
SEM, Two-tailed unpaired t-test.
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Granzyme B+ cells) (Fig. 7e, f). IHC for F4/80, CD163, and MPO
was performed and a significant increase in MPO+neutrophils
was found in primary tumours upon Dox+Zol treatment
compared to any other treatment (Supplementary Fig. 6). Based
on the cell signature plots, Anakinra exerted an anti-
inflammatory effect, by reducing the abundance of every
immune cell type. Taken together, these data suggest that the
specific combination treatment is effective at reducing primary
tumour growth and distant recurrence in bone and other organs







































































































































































































C. Tulotta et al.
9
Published in partnership with the Breast Cancer Research Foundation npj Breast Cancer (2021)    95 
DISCUSSION
Herein, we show that microenvironment-derived IL-1B has
opposite function at different sites: IL-1B supports the develop-
ment of breast cancer bone metastasis, whilst also reducing
tumour growth at the primary site. These results are concordant
with our previous findings on the pharmacological inhibition of IL-
1B signalling by repurposing Anakinra or Canakinumab, which is
already approved for the treatment of auto-inflammatory
diseases11. Inhibition of IL-1B signalling has been shown to have
an anti-tumour effect in the CANTOS trial, in that patients with
previous myocardial infarction and high C-reactive protein levels
assigned to receive Canakinumab, displayed reduced lung cancer
mortality31,32.
Here, we suggest that increased primary tumour growth upon
IL-1B inhibition in the microenvironment is associated with
microenvironment-derived IL-1B promoting the infiltration of
innate immune cells that may display anti-tumour functions.
These results align with data published by others, which
demonstrate that inhibiting IL-1B signalling using the IL1R1
receptor antagonist reduces myeloid cell accumulation at the
primary tumour site in E0771 syngeneic murine models33.
Similarly, IL-1B has been found to promote the infiltration of
monocytes and their differentiation into macrophages within the
primary tumour19. In support of our findings that IL-1B drives the
infiltration of innate immune cells with putative tumour-killing
capacity, by inhibiting M2-like macrophages, we found a reduction
in CD34+ blood vessels in tumours overexpressing IL-1B. We also
observed that IL-1B promotes macrophage recruitment to the
primary tumour site, potentially controlling macrophage polarisa-
tion and localisation. However, in contrast with our findings,
macrophages recruited to the primary tumour have been
described to differentiate towards a tumour-supporting pheno-
type19. We suggest that the use of different murine strains might
explain this divergence. In melanoma models, IL-1B has been
shown to increase the anti-tumour potential of T helper 1 (Th1)
cells34. We assessed the infiltration of CD8+ T cells in primary
tumours from wild-type and IL-1B overexpressing E0771 tumour
cells in IL-1Bfl/fl and IL-1B−/− microenvironments. We observed a
shift in T cell infiltration (Supplementary Fig. 7). Interestingly, CD8+
T cell infiltration upon injection of IL-1B overexpressing E0771
cancer cells mirrored the infiltration pattern of F4/80+ macro-
phages. We speculate that this may further support our hypothesis
that tumour-derived IL-1B restores an anti-tumour immune
response. However, these trends were not statistically significant,
hence the role of the adaptive immune system in our models
remains to be determined. It is also important to consider that the
in vivo models used in this work allow for a rapid development of
primary tumour growth and bone metastasis, and therefore do
not take into account the role of IL-1B in the context of chronic
inflammation that associates with tumour development. To our
knowledge, there are currently no immune competent mouse
models that enable us to investigate effects of IL-1B on the
indolent stage of bone metastasis or effects on slow growing
tumours. However, our previously published data, using T cell
deficient mice, have demonstrated that inhibiting IL-1B or IL1R
signalling can both hold disseminated tumour cells in a dormant
state in bone preventing metastatic outgrowth and slow down
growth of established tumours in bone13,15. It should be noted
that, our work does not take into account IL-1A. Indeed, IL1R1 can
be activated by both IL-1B and IL-1A. In a transgenic model of
luminal breast cancer, IL-1A is tumour-suppressive and correlates
with better prognosis in patients35. A similar function for IL-1A and
IL-1B has also been reported: IL-1A and IL-1B produced by breast
cancer cells can display the same function by equally activating
IL1R1 in lung fibroblasts, which support metastatic colonisation36.
Further work is required to investigate the functional significance
of this IL-1 family member in bone metastasis.
Our previous work suggests that IL-1B drives breast cancer
metastasis in humanised models by inducing EMT at the primary
tumour11. In line with these results, we found that overexpression
of IL-1B signalling in murine mammary tumour cells reduced
proliferation and increased migration in vitro, supporting the
hypothesis that IL-1B drives EMT. In line with our results, immune
cell-derived IL-1B promotes a mesenchymal phenotype in
metastasis initiating cells and prevents metastatic colonisation,
reducing the outgrowth of distant metastases14. However, only
lung metastasis was investigated in this study, and IL-1B may have
a different effect on MIC colonisation within bone.
In bone metastasis, IL-1B displays a tumour-supportive function
and may control myeloid cell number. We speculate that in
response to cancer-associated inflammation at the primary site, IL-
1B is produced systemically and drives the mobilisation of
immune cells from the bone marrow. This has the potential to
reduce the number of immune cells patrolling bone, hence
supporting the development of bone metastasis. In particular, in
contrast to the primary tumour site, we found a decrease in
neutrophil number. It has been proposed that IL-1B promotes the
recruitment of anti-tumour neutrophils to the lung metastatic
niche, consequently reducing metastasis37. This implies that IL-1B
may have different effects on neutrophil recruitment in bone
versus other sites, which is concordant with our data that
microenvironment-derived IL-1B promotes the recruitment of
anti-tumour neutrophils to the primary tumour site, but reduces
recruitment to bone. However, published studies have demon-
strated that microenvironment-derived IL-1B produced by macro-
phages induces the mobilisation of a different subset of
neutrophils, with an immunosuppressive and pro-metastatic
phenotype16 and that, in turn, extracellular traps produced by
neutrophils induce IL-1B production by macrophages in inflam-
matory diseases38,39. It is to be considered that in the bone
marrow of IL-1B−/− mice the lack of bone metastases may be
responsible for the increase of neutrophils. In cancer, neutrophils
have been reported to have both anti-tumour and pro-tumour
functions. The state of maturation of neutrophils can be different
depending on the tissue, where they are located and their
function in cancer can be different depending on their maturation
Fig. 6 Combining Anakinra with Doxorubicin and Zoledronic acid reduces primary tumour growth, distant recurrence and bone
metastasis in breast cancer. a Primary tumour volume in Placebo (P) (day 2: n= 11 tumours (n= 8 mice), day 5: n= 11 tumours (n= 7 mice),
day 12: n= 13 tumours (n= 7 mice)), Anakinra (A) (day 2: n= 9 tumours (n= 7 mice), day 5: n= 9 tumours (n= 6 mice), day 12: n= 13 tumours
(n= 8 mice), Dox and Zol (DZ) (day 2: n= 8 tumours (n= 6 mice), day 5: n= 15 tumours (n= 8 mice), day 12: n= 15 tumours (n= 8 mice)),
Anakinra, Dox, and Zol (ADZ) (day 2: n= 8 tumours (n= 5 mice), day 5: n= 13 tumours (n= 8 mice), day 12: n= 13 tumours (n= 7 mice)). Data
are mean +/− SEM, two-way ANOVA with Tukey’s multiple comparisons test (A vs. P *P= 0.01, A vs. DZ **P= 0.002, A vs. ADZ ***P= 0.0001).
b, c PCNA+ and Cleaved-Caspase 3+ cells (%) in primary tumours. Each data point represents one or more tissue sections from an individual
primary tumour. Data are mean +/− SD. One-way ANOVA with Tukey’s multiple comparisons test (P vs. ADZ *P= 0.04, A vs. ADZ *P= 0.02).
Scale bar = 50 µm. d Casp3+ IHC. e, f Metastases (%) and BLI images (P (n= 7 mice), A (n= 8 mice), DZ (n= 8 mice), or ADZ (n= 7 mice)).
Fisher’s exact test: *P= 0.02 P vs. ADZ (bone metastases); *P= 0.04 DZ vs. ADZ (lung metastases). g, h Animals with metastases (%) (P (n= 6),
A (n= 6), DZ (n= 6), or ADZ (n= 6)) (intra-cardiac injection of E0771 luc2 GFP cells). i, j Animals with metastases (%) P (n= 8), A (n= 8), DZ
(n= 8), or ADZ (n= 7) (intra-cardiac injection of 4T1 luc2 cells). k–m BV/TV % in tibiae from the spontaneous metastasis (k) and overt bone
metastasis (L-C57BL/6, M-BALB/c) models.
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state40,41. We used different markers to identify neutrophils, hence
microenvironment-derived IL-1B may differentially regulate the
recruitment of different subsets of neutrophils at different sites. In
our model, IL-1B drives the recruitment of innate immune cells
that may elicit an anti-tumour response, irrespective of the source.
Both tumour and microenvironment-derived IL-1B induce the
recruitment of immune cells with a pro-inflammatory, anti-tumour
profile. Establishing the function of these immune cells requires
future investigations.
Fig. 7 Combining Anakinra, Doxorubicin, and Zoledronic acid affects tumour-associated immune signatures in a syngeneic model of
spontaneous breast cancer metastasis to bone. a PCA plot. Each dot corresponds to a primary tumour from each treatment group (A or DZ).
b Hierarchical clustering of the 28 differently regulated genes between primary tumours treated with A (n= 5 primary tumours from five
animals) and DZ (n= 6 primary tumours from six animals). c Single and d facet plot of immune cell type score in primary tumours developed
in C57BL/6 mice orthotopically inoculated with E0771 luc2 GFP and treated with A, DZ, ADZ, or control (P). e Representative
immunohistochemistry images of CD8+ T cells in primary tumours of end-stage mice treated with P, A, DZ, or ADZ. Data are mean +/− SEM,
One-way ANOVA with Tukey’s post-hoc test, ns. f Representative immunohistochemistry images of Granzyme B+ cells in primary tumour from
control mice, corresponding lymph node and lymph node from tumour-naïve mice. Scale bar = 50 µm.
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The role of IL-1B in cancer is controversial. Although our work
suggests that IL-1B drives the infiltration of innate immune cells
with potential anti-tumour functions, others have found that IL-1B
creates an immunosuppressive microenvironment that facilitates
distant metastasis by enhancing the infiltration of myeloid-
derived-suppressor cells, which suppress cytotoxic T cell and DC
activity19,42. Hence, coupling anti-IL-1B treatment with immu-
notherapies could be beneficial. Current clinical trials are
recruiting patients to investigate the safety and efficacy of the
IL-1B antibody, Canakinumab, alongside immunotherapies such as
the immune checkpoint inhibitors Spartalizumab and Pembroli-
zumab in breast cancer and other tumour types (ClinicalTrials.gov
Identifier: NCT03484923, NCT03631199, NCT03968419, and
NCT03742349). However, the function of IL-1B as a critical
inflammatory cytokine driving the immune response to patho-
gens, and the risks associated with inhibiting its function in
patients should be taken into account. Additionally, our data
suggest that although inhibition of IL-1B has the potential to
reduce bone metastasis, primary tumour growth may increase.
Surgical resection of the primary tumour alongside IL-1B targeting
may be appropriate.
Breast cancer patients with bone metastasis are commonly
treated with the anti-resorptive agent Zol. Clinical trials have
shown that adjuvant Zol in combination with chemotherapy
reduces bone metastasis in patients with early breast cancer25.
However, an increase in metastasis in other sites has been
observed in pre-menopausal women receiving this treatment
regime25,43. In addition, in line with other published reports33,
Anakinra treatment, when administered alone, may enhance non-
skeletal metastasis. Here, we found that combining standard of
care with Anakinra reduces the growth of the primary tumour,
bone metastasis as well as recurrence in other organs. Importantly,
lung metastasis was significantly reduced upon combination
treatment compared to Dox+Zol. Studies showing the use of
Anakinra after administration of chemotherapy (Paclitaxel) have
reported a slight reduction in primary tumour growth and an
increase in lung metastasis33. This data may suggest that the
timing of exposure to anti-IL1R1 treatment as well as the type of
chemotherapy administered may play critical roles in the anti-
tumour efficacy when combining with Anakinra. Doxorubicin is a
known inducer of immunogenic cell death44, Zol has been
reported to display pro-inflammatory functions45,46, whilst Ana-
kinra is a well-known anti-inflammatory drug47. Interestingly, Zol
has been reported to boost the immunogenicity of other forms of
cell death, which are generally non-immunogenic, therefore
boosting the host immune response against cancer48. By
inhibiting IL-1A and IL-1B binding to IL1R1, Anakinra reduces the
immunosuppression caused by myeloid-derived suppressor cells
and impairs autoinflammation caused by IL-1A-dependent IL-1B
stimulation49,50. Considering the immune-modulatory effects of
each treatment, we sought to understand whether the combina-
tion treatment alters the immune response. We found that
Anakinra displays an opposite immune-related signature com-
pared to Dox and Zol. We suggest that Dox and Zol induce a pro-
inflammatory anti-tumour response, that although initially bene-
ficial, can lead to the onset of immunosuppression due to
sustained inflammation and the development of a pro-tumour
response. Hence, adding an anti-inflammatory drug like Anakinra
is needed to halt this transition and rebalance an effective
immune response against metastatic breast cancer. The combina-
tion therapy initiates a pro-inflammatory anti-tumour response
that is subsequently exhausted (no detectable Granzyme B+ cells
and influx of Treg cells) in mammary tumours. Combining
Anakinra with standard of care Dox+Zol in pre-menopausal
women may be beneficial in reducing the immune-suppressive
effect of Oestrogen whilst boosting the anti-tumour effect of
Dox+Zol. Oestrogen and Zol have opposite effects on the
infiltration and action of T regulatory cells and polarisation of
macrophages, with oestrogen interfering with Zol-driven anti-
tumour immune response. This potentially explains the differential
effect of Zol in pre-menopausal and post-menopausal women. We
are currently investigating molecular mechanisms underpinning
the differential effects of Zol in pre-menopausal and post-
menopausal women51.
Here, we propose that combining Anakinra with standard of
care treatment affects the immune response and as a result




In vivo experiments were performed using 6–8-week-old female IL-1Bfl/fl52
(control) or IL-1B−/− mice (C57BL/6J background), IL1R1fl/fl (control)27,
IL1R1−/− mice (C57BL/6J background)27, C57BL/6J and BALB/c. Ubiquitous
knockout for IL-1B was obtained by backcrossing PGK;Cre; IL-1Bfl/fl to IL-
1Bfl/fl mice (Supplementary Fig. 1). The knockout was confirmed by









Geno F1: TGTTGGGTGATCTCCGTTGA/Geno R2: CCCTGGCTGCTTTTATGA
CT.
Genotyping protocol for PGK:Cre and IL-1B were kindly provided by Dr.
Allan Lawrie (University of Sheffield) and Dr. Emmanuel Pinteaux
(University of Manchester), respectively. Genotyping was performed by
BioServ UK Ltd. Reduced Il-1b gene expression in IL-1B−/− mice was
confirmed using real-time PCR (Supplementary Fig. 1C). Briefly, RNA was
extracted from lung tissues of IL-1Bfl/fl and IL-1B−/− naive mice. Lungs were
homogenised in TRI reagent followed by centrifugation in QIAshredder
columns (QIAGEN). Aqueous solution containing RNA was obtained by
adding chloroform and RNA precipitated in isopropanol, according to the
TRI reagent® protocol (Sigma-Aldrich). cDNA synthesis was performed
using LunaScript RT SuperMix Kit following manufacturer’s instructions
(New England BioLabs). Real-time PCR was performed using Taqman
universal PCR master mix (4304437, Applied Biosystems) and 7900HT PCR
system (Applied Biosystems) (Genomic Core Facility, University of
Sheffield). To measure Il-1b expression, Taqman probe, Mm00434228_m1
(ThermoFisher) was used. GAPDH and B-actin were used as housekeeping
genes (GAPDH: Mm99999915_g1, B-actin: Mm02619580_g1, Thermo-
Fisher). Fold change in gene expression was calculated using the ΔΔCT
method. IL1R1fl/− were kindly provided by Dr. Emmanuel Pinteaux
(University of Manchester). IL1R1fl/fl and IL1R1−/− were obtained by IL1R1¯/-
incross and genotypes confirmed as previously described27. Food and
water were provided ad libitum. Mice were maintained on a 12 h light:12 h
dark cycle. In vivo procedures were conducted in accordance with local
guidelines and with UK Home Office approval under Project License (PPL)
70/8964 or P99922A2E, University of Sheffield, UK.
Cell lines and in vitro studies. Murine mammary tumour E0771 Luc2 V5
GFP, E0771 Luc2 V5 IL-1B GFP, and E0771 Luc2 V5 IL1R1 cell lines were
generated using lentiviral transduction (Supplementary Fig. 2). The
following plasmids were used for overexpression studies: IL-1B
(MR226719L4, Origene), IL1R1 (MR227508L4, Origene), GFP (17448 pLenti
CMV GFP Puro (658-5), Addgene), Luciferase (21474 pLenti CMV V5-LUC
Blast (w567-1), Addgene). For lentiviral transduction, HEK293T cells were
transfected with one of the above expression vectors and packaging
plasmids pMD2.G and psPAX2, kindly provided by R. Bishop (University of
Sheffield). Twenty-four to forty-eight hours of post-transfection, viral
particles were collected, filtered (0.45 µm) and stored at −80 °C. Virus
concentration was measured using Lentivirus-Associated p24 ELISA Kit
(VPK-107, Cell Biolabs). E0771 cells were seeded in a 24-well plate (2.5 ×
104/well) and lentivirus particles (2 moi) added with polybrene for 24 h.
Puromycin (2 µg/ml) or Blasticidin (20 µg/ml) were used for selection.
Overexpression of IL-1B and IL1R1 was confirmed via real-time PCR
as previously described (Taqman probes: Mm00434228_m1 (Il-1b),
C. Tulotta et al.
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Mm00434231_m1 (Il1r1), Mm99999915_g1 (Gapdh) and Mm02619580_g1
(B-actin)) and enzyme-linked immunosorbent assays (ELISA MAXTM Deluxe
Set Mouse IL-1B kit (BioLegend) and Mouse IL1R1 ELISA Antibody Pair Set
(Sino Biological, SEK50807). Cell viability was assessed using MTT according
to the manufacturer’s instruction (M5655-1G, Sigma-Aldrich). For cell
migration, E0771 control, IL-1B overexpressing or IL1R1 overexpressing
cells were incubated with 10 µg/ml Mitomycin C (Sigma-Aldrich, M-0503)
for 3 h. Cells were collected, washed in PBS and resuspended in 0.1% w/v
BSA RPMI 1640 (serum free). 1 × 105 cells were added into the inner
transwell (6.5 mm diameter inserts, 8 µl pore size, 3422, Costar) in a 24-well
plate. Six hundred microliter complete medium was added to the main/
outer well. Cell migration was quantified 24 h after seeding. Cells were
fixed by washing the transwell membrane in 100% v/v ethanol (5 min) and
stained with 1% w/v eosin (1 min) and haematoxylin solution (5 min).
Membranes were mounted on slides using aqueous mounting solution
(S3025, DAKO). Images of four different fields of view (FOV) were acquired
from each cell line using InvitrogenTM EVOSTM FL auto imaging system
(Thermo Fisher Scientific) (20× objective). Cell migration was quantified by
image analysis using ImageJ.
Cell lines were cultured in RPMI 1640 Medium, GlutaMAXTM (GibcoTM)
containing 10% v/v foetal bovine serum (FBS). E0771 luc2 GFP and 4T1 luc2
were cultured in RPMI+10% v/v FBS (Gibco, Invitrogen). As described by
ATCC, The E0771 mammary tumour was first reported in 1948 as a
spontaneous mammary carcinoma arising in a C57Bl/6 mouse (https://www.
lgcstandards-atcc.org/products/all/CRL-3461.aspx#generalinformation).
E0771 luc2 GFP were kindly provided by Professor Sandra McAllister’s
laboratory (Department of Medicine, Harvard Medical School, Boston, MA,
USA). The E0771 cells used in the current study have been selected for their
bone homing capabilities following two rounds of intra-cardiac tumour cell
injection, in which bone metastatic clones have been isolated and re-
injected. 4T1 luc2 were kindly provided by Ryan Bishop (Department of
Oncology and Metabolism, University of Sheffield, UK).
All cell lines were cultured at 37 °C in a humidified incubator under 5% v/v
CO2. Cells were routinely checked for mycoplasma infection.
In vivo studies
Syngeneic model of primary tumour growth. 12.5 × 104 E0771 luc2 GFP,
luc2 V5 GFP, IL-1B GFP, or IL1R1 GFP cells were engrafted via intra-ductal
injection into IL-1Bfl/fl, IL-1B−/−, IL1R1fl/fl, or IL1R1−/− mice immediately
following injection of 0.003mg Vetergesic. Tumour growth was measured
using bioluminescence-based in vivo imaging (IVIS Lumina II in Vivo
Imaging System (PerkinElmer) and Living Image® 4.5.4 software), once per
week, 2–4min following subcutaneous injection of 6 mg/kg D-Luciferin
(Invitrogen). BLI thresholds have been modified across experimental
models to allow the visualisation of tumour-derived bioluminesce signal.
Procedures were ended when tumour size reached 1 cm3 in either the
control or treatment group and according to the original, planned,
experimental protocol.
Syngeneic model of experimental overt bone metastases
2.5 × 104 E0771 luc2 V5 GFP, IL-1B GFP, or IL1R1 GFP cells were inoculated
systemically via injection into the left cardiac ventricle of IL-1Bfl/fl or
IL-1B−/− mice. Tumour development in organs and bone was measured
using bioluminescence imaging, as described above. Procedures were
ended one week following detection of bone metastases.
Combination therapy. A syngeneic orthotopic model was used to study
spontaneous breast cancer metastasis to bone. 1.25 × 105 E0771 luc2 GFP
were administered to 6–8 week-old C57BL/6J female mice via intra-ductal
injection (4th mammary ducts). Mice were randomised 9 days after tumour
cell injection to Placebo (P) (n= 8), Anakinra (n= 8), Doxorubicin and
Zoledronic Acid (Dox and Zol) (n= 8) and Anakinra in combination with
Dox and Zol (n= 8). Mice received a daily subcutaneous injection of
Anakinra (1 mg/kg) or Placebo or intravenous 2mg/kg/week Dox injection
followed 24 h later by subcutaneous injection of Zol (100 µg/kg/week).
Placebo and Anakinra (r-metHu1L-ra) were obtained from Amgen, Cam-
bridge, UK. Dox and Zol were obtained from Pharmachemie B.V. and
Novartis Pharma AG, respectively. Tumour growth was measured using
bioluminescence-based in vivo imaging (IVIS Lumina II In Vivo Imaging
System (PerkinElmer) and Living Image® 4.5.4 software) and using calipers.
Mice were culled 23 days after tumour cell injection. Primary tumours were
either fixed in 4% w/v PFA in phosphate buffered saline (PBS, PFA/PBS) or
stored at −80% in FCS+10% v/v dimethyl sulfoxide (DMSO). Bones (hind
limbs), lungs and liver were imaged ex vivo to detect metastasis.
In order to study overt bone metastasis, intra-cardiac injection of E0771
luc2 GFP (2.5 × 104 cells) or 4T1 luc2 (0.5 × 105 cells) was performed in
6–8 week old C57BL/6J or BALB/c (Charles Rivers), respectively. Mice were
imaged using bioluminescence imaging before being randomised in the
following treatment groups: Placebo (6–8 mice), Anankinra (6–8 mice), Dox
and Zol (6–8 mice), Anakinra, Dox and ZOL (6–8 mice). Pharmacological
treatments were started 3 days after tumour cell administration.
Compound injections were performed as described for the spontaneous
metastasis model. Metastasis formation was monitored using IVIS imaging,
as described above. Mice were culled 16 days (E0771/C57BL/6J model) and
10–13 days after tumour cell injection (4T1/BALB/c model).
Sample collection. Primary tumours, tibiae, lungs, liver, and spleen were
fixed in 4% w/v PFA/PBS for 48 h at 4 °C or stored at −80 °C in FBS+v/v
10% DMSO. Following blood collection, serum was obtained by
centrifugation and stored at −80 °C. Bone marrow was collected from
femurs via centrifugation and stored at −80 °C in 0.2 ml FBS+10% v/
v DMSO.
Histology and immunohistochemistry. Fixed tissues were embedded in
paraffin, sectioned at 3 µm and stained with H&E or used for
immunohistochemistry (antibodies and antigen retrieval were performed
as described in Supplementary Table 1). Briefly, paraffin-embedded
sections were dewaxed and rehydrated. 3% v/v H2O2 in methanol was
used to block internal peroxidase activity for 10min, followed by antigen
retrieval. Incubation with primary antibodies was overnight at 4 °C.
Secondary antibodies were added for 30min at room temperature (RT).
ABC kit and DAB were used to amplify and visualise antibody binding prior
to counterstaining with Gill’s Haematoxylin. Tissue sections were digitally
scanned using Panoramic 250 Flash III slide scanner (3DHISTECH).
Quantification of percentage of positive cells was performed using QuPath:
Open source software for digital pathology image analysis53. Percentage of
positive cells was calculated over the total number of cells (positive and
negative for each cell marker assessed). These quantifications were
performed considering the whole slide scanned.
Flow cytometry. Cryopreserved bone marrow was defrosted and washed
in ice-cold PBS supplemented with 1% v/v FBS (FACS buffer). Samples were
aliquoted and incubated with fluorochrome-conjugated antibodies and
live/dead dye (Supplementary Table 2) (diluted 1:100) for 45min on ice.
After washing in FACS buffer, samples were resuspended in 500 µl FACS
buffer. Data acquisition was performed on a BD LSRII™ flow cytometer and
analysed using FlowJo, LLC. Gating strategy is reported in Supplementary
Fig. 8.
µCT imaging. µCT analysis was carried out using a Skyscan 1172 X-
ray–computed µCT scanner (Skyscan) equipped with an X-ray tube
(voltage, 49 kV; current, 200mA) and a 0.5-mm aluminium filter. Pixel size
was set to 4.3 µm and scanning initiated from the top of the proximal tibia
as described previously22,24.
NanoString nCounter™ gene expression profiling. To assess the immune
profile of primary tumours upon treatment, the NanoString nCounter™
panCancer Immune profiling panel (NanoString Technologies) was used.
Primary tumours were homogenised using QIAshredder (Catalogue
number: 79654, Qiagen) and RNA isolated using RNeasy mini kit (Cat
number: 74101, Qiagen). One hunderd and fifty nanogram RNA (50 ng/µl)
was used for NanoString analysis, according to the manufacturer’s
recommended protocols. Transcriptomic analysis was performed using
nSolverTM 4.0 and Advanced Analysis 2.0 (NanoString Technologies).
Principal component analysis and differential gene expression testing
between primary tumours treated with Anakinra or Dox and Zol was
performed using Qlucore Omics Explorer. GO analysis was performed on
differentially expressed genes in the Anakinra and Dox and Zol treatment
groups, using g: Profiler (version e99_eg46_p14_f929183)54 and Metas-
cape55. Genes were considered differentially expressed after setting P-
value and FDR < 0.05 and absolute fold change ≥2. Cell-type deconvolu-
tion across treatment groups was performed in R; gene expression
intensities were mean-centred across all samples before calculating raw
cell-type signature scores as the mean average of log2 expression
intensities for all genes in each cell-type signature. Signatures genes for
each cell type were determined with reference to Nanostring document
LBL-10043-08 (nCounter PanCancer Immune Profiling Panel Gene List.xlsx).
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Statistical analysis
Data analysis were performed using GraphPad Prism 7.02 and 8.02
(GraphPad Software Inc.). Outliers were identified by ROUT (Q= 1%) test
and removed before statistical analyses were conducted. Information on
data sets and statistical analysis for each experiment is reported in the
main text and figure legends. P < 0.05 was considered statistically
significant. Graphs showing percentage of animals with metastases also
display the number of mice with metastases over the total number of mice
in each treatment group. Graphs displaying single data points can be
found in Supplementary Fig. 9.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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